FDA Approves Lilly's Humalog
Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia.
Humalog has a more rapid onset and a shorter duration of action than human regular insulin. Therefore, in patients with type 1 diabetes, Humalog should be used in regimens that include a longer-acting insulin. However, in patients with type 2 diabetes, Humalog may be used without a longer-acting insulin when used in combination therapy with sulfonylurea agents.
Humalog may be used in an external insulin pump, but should not be diluted or mixed with any other insulin when used in the pump.
Humalog, an insulin analog of recombinant DNA origin, has been approved for the treatment of type I and type II diabetes. Humalog is the first of a new type of insulin that is designed to mimic the body's own normal rapid insulin response.
Humalog is used to treat type 1 (insulin-dependent) diabetes in adults. Insulin lispro is a fast-acting form of insulin. It is usually given together with another long-acting insulin. It works by lowering levels of glucose in the blood.
Humalog is also used together with oral (taken by mouth) medications to treat type 2 (non insulin-dependent) diabetes in adults.
Humalog is a new type of insulin that more closely mimics the body's natural insulin response after eating a meal. Humalog offers people with diabetes an additional resource with which to manage their disease -- one that is more flexible and convenient than traditional insulin therapies.